Slovenia's pharma group Krka saw its net profit increase by 13% in 2024 to €353.4 million as sales revenue rose by 6% to a record €1.91 billion, according to an unaudited performance estimate released by the company.

"We recorded the strongest sales since incorporation and saw sales grow in the majority of our markets, most substantially in region East Europe," CEO Jože Colarič was quoted as saying in the estimate.

The Novo Mesto-based group generated 34.2% of its revenue in East Europe region, 22.4% in Central Europe, 18.5% in West Europe and 14.2% in South-East Europe. 6.4% of its revenue was generated in Slovenia and another 4.3% in overseas markets.

Broken down by groups of products, prescription drugs accounted for 82.5% of the revenue, over-the-counter drugs for 9%, animal health products for 5.9% and spa and tourism services for 2.6%.

Colarič said the group "obtained marketing authorisations for 22 new products, and completed more than 1,000 marketing authorisation procedures in various countries".

Earnings before interest, tax, depreciation and amortization (EBITDA) reached €518.2 million, and earnings before interest and taxes (EBIT) were up by 7% on 2023 to €425.7 million.

Investments totalled €117 million, focusing on improvements in production technologies, development, and quality.

At the end of 2024, Krka employed 12,810 people, 41% of them outside Slovenia. Of all employees, 47% had at least university-level qualifications.

This year, Krka expects to generate a record revenue of €2 billion and a profit of €365 million, some €11 million more than originally planned. It plans to spend €150 million on investments.